Hemophilia seen through children’s eyes: Kedrion teams up with LA Kelley
Three books of the series My First Factor Creation are now available for free download
Kedrion Biopharma consolidates presence on Russian market
Joint venture with Nacimbio of RosTECH group for a technology transfer to Kirov plant
SIPPET study results published in the “New England Journal of Medicine”
This investigator-initiated clinical study involved 42 hemophilia treatment centers from all over the world
‘For the Town of Gödöllő’ prize is awarded to HUMAN BioPlazma staff
For their professionality and community involvement
CURhE, Global Alliance for mother and child healthcare
Kedrion among the founding members. The aim is Rh disease eradication
Kedrion Biopharma strengthens its position on the US market
Granted exclusive rights to commercialize a lifesaving drug in the US
A brand new location for KEDPlasma donors in the very center of Fürth
Plasma collected is turned into life-saving therapies to serve patients in Germany and worldwide
KEDPlasma acquires two plasma centers from ImmunoTek LLC in the US
The acquisition is part of a five-year growth plan of supplying highest-quality plasma to Kedrion Biopharma
Hemophilia A. SIPPET study selected by the American Society of Hematology
Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies
Humanitarian programme to reduce the gap in the access to clotting factors
Kedrion helps the WISH project come true: Italian CNS and the World Federation of Hemophilia sign agreement in London